StockWatch
·

DCX Systems Ltd Q2 FY27 Results

DCXINDIAQ2 FY27 Results
Filing
Result:Weak· Market: Surged#Cost led#Margin expansion
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue140.1735.9%27.3%
Total Income148.0932.3%27.7%
Expenditure146.2123.6%30.4%
PBT1.88129.3%135.4%
Net Profit-0.2697.0%97.2%
OPM-0.85%9.51pp5.80pp
NPM-0.17%7.57pp4.24pp
EPS-0.02102.6%102.5%
View full financials

Defence/manufacturing core metric is revenue growth, which fell 27.3% YoY and the group stayed in a net loss (margin-led narrowing, not a turnaround), so it's below-par for the sector despite the cost-driven improvement in margins.

Q2 FY-2027 RESULTS · DCXINDIA

DCX Systems narrows loss to ₹0.3 Cr on margin recovery; revenue still down 27% YoY

PAT +97.16% YoY · revenue -27.32% · margins expanding

11 Nov 2026 · 3 min read
Revenue

₹140.17 Cr

-27.32% YoY

PAT (consolidated)

₹-0.26 Cr

+97.16% YoY

Net margin

-0.17%

+4.2pp YoY

EPS

₹-0.02

DCX Systems' consolidated results for Q2 FY27 (quarter ended September 30, 2026) show a net loss of ₹0.26 Cr, down sharply from a ₹9.04 Cr loss in Q2 FY26 and an ₹8.66 Cr loss in Q1 FY27 — a roughly 97% narrowing on both counts. Consolidated revenue was ₹140.17 Cr, down 27.3% YoY from ₹192.85 Cr, though up 35.9% QoQ off Q1 FY27's execution-delay-hit base of ₹103.13 Cr. On a YoY basis — the primary read — this is a loss that is narrowing rather than a turnaround: the bottom line stayed negative even as the scale of the loss shrank materially against a still-declining topline.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹140.17 Cr+35.9%-27.3%
Expenses₹146.21 Cr+23.6%-30.4%
PAT₹-0.26 Cr+97.03%+97.16%
Net margin-0.17%+7.6pp+4.2pp
EPS₹-0.02-102.6%-102.5%

The improvement is margin-led, not volume-led. Net margin recovered to -0.18% from -4.69% a year ago and -8.40% last quarter; EBITDA margin (OPM) improved to -0.85% from -6.65% YoY and -10.36% QoQ. There are no exceptional items in either period, so the move is genuine — cost growth lagged the QoQ revenue recovery, and the other-expense line swung from a ₹3.13 Cr forex loss a year ago to a small forex gain this quarter. Tax expense of ₹2.11 Cr was roughly flat against a near-breakeven pre-tax line (₹1.86 Cr), which is what tipped the group back into a small net loss despite the positive operating trend.

₹
126.23140.87155.51170.15184.79146.408-1009-0109-2410-1911-11Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹146.4, down 3.7% over the past month of trading.

₹ Cr
-10.61-5.20.225.634.06Q1 FY26rev ₹222 Cr-9.04Q2 FY26rev ₹193 Cr-2.43Q3 FY26rev ₹121 Cr-0.3Q4 FY26rev ₹207 Cr-8.66Q1 FY27rev ₹103 Cr-0.26Q2 FY27rev ₹140 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Basis matters here: standalone (parent-only) swung to a profit of ₹4.29 Cr (EPS ₹0.39) on revenue of ₹138.23 Cr, while consolidated — the primary basis — posted the ₹0.26 Cr loss (EPS -₹0.02). The ~₹4.55 Cr gap is entirely subsidiary-driven: RASPL and R&D-stage NIART, which the filing notes is still pre-commercial-production and expensing development costs, plus a marginal share of ELTX associate loss. No analyst consensus estimate specific to this quarter turned up in a web search, so vs-street is unknown; management has issued no formal guidance either in our records or via search, so vs-guidance is unknown too — Q1 FY27 brokerage previews had flagged that quarter's revenue as significantly below estimates on execution delays, and this quarter's YoY revenue decline continues that theme in degree even as losses narrow. The quarter's other disclosed developments — ₹18.28 Cr of new orders (Aug 2026) and a Tamil Nadu government JV MoU (Aug 2026) — are both too small or early-stage to have moved this quarter's numbers; the insider-trading window closure (Sept 28) was routine. No management press-release commentary was available to cross-check against the print.

  • W1

    Whether Q3 FY27 revenue sustains the QoQ recovery to ~₹140 Cr or reverts to the execution delays flagged in Q1 FY27 (₹103 Cr)

  • W2

    Whether RASPL/NIART R&D-stage losses (₹4.55 Cr combined this quarter) narrow as NIART's product nears commercial production, per the filing's own note

  • W3

    Whether consolidated PAT crosses into profit, given the loss has narrowed from ₹9.04 Cr (Q2 FY26) to ₹8.66 Cr (Q1 FY27) to ₹0.26 Cr (Q2 FY27)

Informational and educational content only. Not investment advice.